Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04169061 · ClinicalTrials.gov registry record · Phase 4
Impact of Acthar on Everyday Life of Participants With Severe Keratitis
A Phase 4 study of Keratitis, sponsored by Mallinckrodt.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 9
- Study locations
NCT04169061 is a Phase 4 study of Keratitis that has completed, run by Mallinckrodt. The registered enrollment target is 36 participants. The trial reports 9 study locations across 7 states.
The verdict
NCT04169061, a Phase 4 study of Keratitis, has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 9
- Study locations
Study Summary
We will need about 36 participants for this study. Volunteers might be able to participate if: * they have bad noninfectious keratitis * early treatments failed or were not well tolerated Participants will be in the study for about 22 weeks: * 4 weeks for tests to see if the study might be good for them * 12 weeks of treatment with Acthar gel * 4 weeks to wean off Acthar gel and follow-up with the doctor
Conditions Studied
Interventions
- DRUG Acthar
Study Locations (9)
California
- Global Research Management, Inc. - Glendale
- Eye Research Foundation - Newport Beach
Tennessee
- Total Eye Care, P.A. - Memphis
- Advancing Vision Research, LLC - Nashville
Arizona
- Cornea and Cataract Consultants of Arizona - Phoenix
Kentucky
- Eye Care Institute - Louisville
Massachusetts
- Andover Eye Associates - Raynham
North Carolina
- Vita Eye Clinic - Shelby
Pennsylvania
- Scott & Christie and Associates, PC - Cranberry Township
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2020-12-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04169061
The ClinicalTrials.gov registry entry for NCT04169061 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Keratitis appearing as the primary indexed condition, and to 1 intervention - of which Acthar is the first listed.
NCT04169061 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Tennessee, Arizona.
Frequently Asked Questions
What is clinical trial NCT04169061 about?
NCT04169061 is a clinical study titled "Impact of Acthar on Everyday Life of Participants With Severe Keratitis". We will need about 36 participants for this study. Volunteers might be able to participate if: * they have bad noninfectious keratitis * early treatments failed or were not well tolerated Participants will be in the study for about 22 weeks: * 4 weeks for tests to see if the study might be good ...
What is the current status of trial NCT04169061?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2019-11-13. Estimated completion is 2020-12-07.
What conditions does trial NCT04169061 study?
This clinical trial studies the following conditions: Keratitis.
What interventions are being tested in trial NCT04169061?
The interventions under investigation include: Acthar (DRUG).
Who is sponsoring clinical trial NCT04169061?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04169061 being conducted?
This trial has 9 study locations across Arizona, California, Kentucky, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.